AeroEclipse II Agreement

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sharon Dell, The Hospital for Sick Children
ClinicalTrials.gov Identifier:
NCT01288482
First received: January 28, 2011
Last updated: May 12, 2014
Last verified: May 2014

January 28, 2011
May 12, 2014
November 2010
September 2011   (final data collection date for primary outcome measure)
  • Methacholine inhalation challenge [ Time Frame: Visit 1(Day 1) ] [ Designated as safety issue: No ]
    A methacholine inhalation challenges will be performed at each of the first two visits. At the first clinic visit each subject will be randomly assigned to use either the English-Wright continuous-mode nebulizer, or the AeroEclipse II breath actuated nebulizer. The alternate nebulizer will be used during the second clinic visit. The methacholine concentration producing a 20% decrease in Forced Expiratory Volume in 1 second (PC20) will be measured by way of a standard breathing challenge (the tidal breathing Cockcroft technique)
  • Methacholine inhalation challenge [ Time Frame: Visit 2 (up to 2 weeks) ] [ Designated as safety issue: No ]
    A methacholine inhalation challenges will be performed at each of the first two visits. At the first clinic visit each subject will be randomly assigned to use either the English-Wright continuous-mode nebulizer, or the AeroEclipse II breath actuated nebulizer. The alternate nebulizer will be used during the second clinic visit. The methacholine concentration producing a 20% decrease in Forced Expiratory Volume in 1 second (PC20) will be measured by way of a standard breathing challenge (the tidal breathing Cockcroft technique)
Same as current
Complete list of historical versions of study NCT01288482 on ClinicalTrials.gov Archive Site
Methacholine challenge - Cumulative Effect [ Time Frame: Week 3 +/- 1 week ] [ Designated as safety issue: No ]
There exists the possibility that as a result of decreased nebulisation time, we may see some cumulative effect from shortening the time between doubling doses of methacholine. If there is a systematic difference between the English-Wright and the AeroEclipse II nebulizers, it will then be impossible to know if we have calculated the wrong dose or we are seeing a cumulative effect. Therefore we are proposing that the first 10 patients participate in a third visit to look for a cumulative effect.
Same as current
Not Provided
Not Provided
 
AeroEclipse II Agreement
Use of the AeroEclipse II Breath Actuated Nebulizer for the Delivery of Methacholine Chloride Bronchoprovocation Agent: A Pilot Study.

Traditional, continuous-mode nebulizers such as the English-Wright nebulizer are designed to operate continuously with tidal breathing. As inhalation accounts for only about one-third of the respiratory cycle, two-thirds of the continuously produced aerosol is lost to the environment possibly posing a hazard any fellow-patients, family members, or health-care workers in the vicinity. The English-Wright has been the only American Thoracic Society (ATS)recommended device available on the market. Recently Roxon Medi-Tech has announced the discontinuation of the English-Wright nebulizer. For these reasons it is necessary to review the use of other nebulizers such as the AeroEclipse II breath-actuated nebulizer and further validate their performance.

The investigators expect to show equivalence between the AeroEclipse II and the English-Wright nebulizers.

This study would like to determine if the use of the Aeroeclipse II breath actuated nebulizer for the delivery of methacholine chloride bronchoprovocation agent to the lungs results in the same Provocation Concentration PC20 (provocation concentration, or dose that causes a 20% decrease in Forced Expiratory Volume in 1 sec or FEV1) as using the English-Wright nebulizer for the delivery of methacholine chloride bronchoprovocation agent to the lungs.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Asthma
  • Device: AeroEclipse II breath-actuated nebulizer
    The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
  • Device: English-Wright continuous-mode nebulizer
    The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
Experimental: Asthma Subjects
Interventions:
  • Device: AeroEclipse II breath-actuated nebulizer
  • Device: English-Wright continuous-mode nebulizer
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Aged 10 to 65 years at time of recruitment into this study,
  2. Diagnosis of current asthma by a health care professional,
  3. Tidal breathing Provocation Concentration ≤ 16 mg/mL,
  4. Forced Expiratory Volume 1> 65% of predicted,
  5. No respiratory tract infection or allergen exposure ≥ 4 weeks,
  6. Able to complete 2 methacholine inhalation challenges on 2 separate days at the same time of day, at least 24-h apart, and within a 2-week period,
  7. Inhaled salbutamol withheld for ≥8 hours prior to testing,
  8. Inhaled corticosteroid maintained at same dose throughout study,
  9. inhaled formoterol and salmeterol withheld for ≥36 hours prior to testing.

Exclusion Criteria:

  1. Those born prematurely (more than 4 weeks early of the calculated date),
  2. Those with chronic health conditions like diabetes or cystic fibrosis,
  3. Smokers.
Both
10 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01288482
1000019446
No
Sharon Dell, The Hospital for Sick Children
The Hospital for Sick Children
Not Provided
Principal Investigator: Sharon Dell, MD The Hospital for Sick Children, Toronto Canada
The Hospital for Sick Children
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP